Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / RNF113A

RNF113A

Basics

Aliases:
This biomarker is also known as:
  • Zinc finger protein 183,
  • Cwc24,
  • ZNF183,
  • ring finger protein 113A,
  • RING finger protein 113A,
  • RNF113,
  • zinc finger protein 183 (RING finger, C3HC4 type),

View in BioMuta

Description…

RNF113A is a member of the RNF family, or RING-type zinc finger proteins. The RNF proteins are a subset of the larger family of zinc finger proteins. Members of the RNF family have an enzyme activity known as E3 ubiquitin-protein ligase which targets other proteins to be degraded within cells. RNF113A contains a C3H1-type zinc finger domain and a C3HC4 Ring-type (Really Interesting New Gene-type) zinc finger domain. The Ring-type zinc finger domain is present in various tumor suppressors, DNA repair genes and cytokine receptor-associated molecules, and is implicated in mediating protein-protein interactions.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: RNF113A

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

RNF113A is a RING-type zinc finger protein. Several RING-type zinc finger proteins act as tumor suppressors. BRCA1 is also a RING-type zinc finger protein, with the same C3HC4 Ring-type zinc finger domain as RNF113A. Mutations in the tumor suppressor BRCA1 are widely known to contribute to the development of breast cancer.

Performance Comment

RNF113A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.